Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Current assets:
Cash	$ 108,624	$ 180,838
Prepaid expenses and other current assets	5,139	3,221
Income tax receivable	1,000	105
Total current assets	114,763	184,164
Deferred tax assets	0	208
Furniture and equipment, net	1,273	906
Other assets	3,065	0
Total assets	119,101	185,278
Current liabilities:
Accounts payable	4,578	3,329
Interest payable	282	0
Accrued expenses	30,265	11,978
Due to Roivant Sciences Ltd., Roivant Sciences, Inc. and Roivant Sciences GmbH	1,960	3,030
Total current liabilities	37,085	18,337
Takeda warrant liability	0	52
Deferred rent	408	113
Deferred interest payable	255	0
Long-term debt	43,624	0
Total liabilities	81,372	18,502
Commitments and contingencies (Note 11)
Shareholders’ equity:
Common shares, par value $0.000017727 per share, 564,111,242 shares authorized, 60,997,856 and 60,275,757 issued and outstanding at March 31, 2018 and 2017, respectively	1	1
Common shares subscribed	0	(1)
Additional paid-in capital	266,178	251,733
Accumulated other comprehensive income	24	140
Accumulated deficit	(228,474)	(85,097)
Total shareholders’ equity	37,729	166,776
Total liabilities and shareholders’ equity	$ 119,101	$ 185,278